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Preamble 
The focus of research for the present Thesis was to establish the best cost-utility 
estimate for the Portuguese population on the use of conventional upper endoscopy 
for the diagnosis of early gastric cancer. 
In light of this, our main aim was to perform an economic analysis on the secondary 
prevention of gastric adenocarcinoma by endoscopic surveillance of patients at high 
risk of progressing from extensive atrophy or intestinal metaplasia conditions to 
cancer. The study was designed for the Portuguese population because Portugal has 
the highest incidence of the disease in Western Europe. 
The knowledge obtained from this project is very important for a Portuguese 
Gastroenterologist that works in an Oncology Institute, not only by answering some 
unsolved questions in the clinical practice pointed out by recent guidelines, such as 
follow-up or not patients at-risk, how, when and at what cost, but also allowing to use 
the obtained know-how in other fields of Gastroenterology. 
The results of the study should be of interest at a national level as the prevalence of 
gastric premalignant conditions is relevant in our country and most gastroenterologists 
in Portugal perform upper endoscopic exams in their clinical practice. 
Furthermore, the results of the model obtained could be replicated in other countries 
as the clinical model should be applicable in other settings, just needing the proper 
adjustments on local costs, providing evidence that could be generalized to 
gastroenterologists worldwide, interested in the problem of gastric cancer.  
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Along with the four specific studies necessary for the present Thesis, the author also 
promoted the work in this field by dissemination of proposals publishing an opinion 
article in an indexed Portuguese journal (Areia, Pimentel-Nunes, Marcos-Pinto, & 
Dinis-Ribeiro, 2013), promoting the search for the best evidence by publishing an 
article on quality of endoscopic reporting in Gastroenterology (Areia, Soares, & Dinis-
Ribeiro, 2010), participating in a gastric cancer book chapter promoted and published 
by the Portuguese Medical Association (Marcos-Pinto, Areia, Pimentel-Nunes, & Dinis-
Ribeiro, 2013), performing a national multicentre cross-sectional study to assess the 
prevalence of gastric premalignant conditions and general performance of endoscopy 
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2014) and participating as a co-author of the guidelines on the Management of 
Precancerous conditions and lesions in the Stomach (MAPS) (Dinis-Ribeiro, Areia et al., 
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Outline of Thesis 
In Chapter I, the rationale to the subject chosen for the present thesis is presented. A 
brief introduction on the gastric cancer problem worldwide and specifically in Portugal 
is offered, along with the available evidence on economic studies on surveillance of 
premalignant conditions and clinical guidelines recommendations by the time of the 
thesis origin. 
In Chapter II, the background that explains the importance of the gastric cancer theme 
is presented along with a description of the gastric carcinogenesis cascade 
assumptions, the relevance of endoscopy for the diagnosis, assessment of extension 
and surveillance of gastric premalignant conditions and how economic studies are 
implemented in the medical field taking in consideration the published guidelines for 
this specific type of studies, justifying our choice on a cost-utility model for the 
endoscopic surveillance of gastric premalignant conditions. 
In Chapter III, the aims of each of the four studies performed along the present thesis 
are presented. 
In Chapter IV, we present the publications that emerged from the present thesis, in its 
final published format. 
In Chapter V, a discussion of all the results of our data is presented. Each result is 
discussed in comparison with the available evidence and the cost-utility model is also 
compared with previous similar reports in terms of strength of evidence and 
dissimilarities. 
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Finally, in Chapter VI, our thesis conclusions are presented and further research is 
identified. 
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Gastric adenocarcinoma represents a health problem worldwide due to its high 
incidence and mortality rates being the fourth most common malignancy and the 
second leading cause of cancer death (Ferlay, Shin et al., 2010). Its prognosis is highly 
dependent of the stage at diagnosis, that usually occurs in advanced stages, requiring 
demanding treatments and costs (Hundahl, Phillips, & Menck, 2000). Although being a 
worldwide problem, different prevalence rates among countries lead to different 
options; in Japan, universal screening of the population using fluoroscopy is used, 
followed by conventional endoscopy with biopsies for the positive results (Hamashima, 
Shibuya et al., 2008) whilst in most other developed countries the low incidence rate 
makes screening not cost-effective (Hirota, Zuckerman et al., 2006). In Portugal, the 
incidence rate for gastric cancer is located in-between these two realities and so, it is 
not straightforward that in our country such a program would be justifiable. 
This type of carcinoma develops after years of progression of a benign condition such 
as non atrophic gastritis that might evolve to premalignant conditions, namely chronic 
atrophic gastritis and intestinal metaplasia, before the development of dysplasia and 
invasive cancer (Correa, 1992). Endoscopy is usually the first exam to perform for the 
diagnosis of these gastric premalignant conditions (Hirota, Zuckerman et al., 2006). 
Based on the assumption that chronic gastritis starts in the antrum and then spreads 
to the corpus in an upward manner so that conditions of the corpus are more 
extensive and related to more advanced stages, it has been suggested to discriminate 
this extensive phenotype as it could imply an increased risk of progression to dysplasia 
and invasive cancer. As so, recent guidelines suggest a 3-yearly endoscopic follow-up 
for these patients, based on clinical data but with no support from the published 
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economic studies due to conflicting results (Dinis-Ribeiro, Areia et al., 2012; Dinis-
Ribeiro, Areia et al., 2012). 
Having Portugal an intermediate-risk population for gastric cancer (GLOBOCAN, 2012), 
to improve our patients quality of live and overall survival, it is important to improve 
our rates of early gastric cancer detection in order to achieve more curative 
treatments by endoscopic resections techniques or detection of invasive cancers in an 
early stage, treatable with less debilitating treatments. 
As so, the objective of the present thesis was to determine the cost-utility of 
endoscopic surveillance every 3 years of patients with extensive gastric premalignant 
conditions compared with no surveillance. To accomplish that goal we first performed 
two systematic reviews and one cross-sectional study in order to obtain the best 
available clinical data for the Portuguese population and then a cost-utility economic 
analysis on this hypothesis. 
Using a Markov model to compare the two strategies and using a societal perspective, 
clinical data was collected from the mentioned systematic reviews of the literature, 
costs from published national data and community utilities derived from the cross-
sectional study by using the EuroQol questionnaire in terms of Quality Adjusted Life 
Years (QALY) (EuroQol, 1990). For the Markov model, the population started at the age 
of 50, a time horizon was set for 25 years and an annual discount rate of 3% was used 
for both costs and effectiveness. 
The results of the model showed that endoscopic surveillance every 3 years provided 
an Incremental Cost-Effectiveness Ratio (ICER) of € 18,336 below the adopted 
threshold of € 36,575 proposed by economic guidelines and this strategy dominated 
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surveillance every 5 or 10 years. Even when the model was evaluated in sensitivity 
analysis, only a few utilities proved to be relevant in deterministic analysis, while 
probabilistic analysis showed that in 78% of simulations the model remained cost-
effective. 
Thus, the conclusion of this thesis is that endoscopic surveillance of patients with 
premalignant conditions such as extensive atrophy or intestinal metaplasia, every 3 
years, in an intermediate-risk country such as Portugal, is cost-effective. 
 
 
  
26 
 
  
27 
 
 
 
 
 
 
 
 
 
 
Resumo 
 
 
  
28 
 
  
29 
 
O adenocarcinoma gástrico representa um problema de saúde global devido às suas 
elevadas taxas de incidência e mortalidade, sendo o quarto tumor maligno mais 
comum e representando a segunda causa de morte por cancro (Ferlay, Shin et al., 
2010). O seu prognóstico é altamente dependente da fase de diagnóstico, que 
geralmente ocorre em estádios avançados, exigindo tratamentos agressivos com 
custos económicos relevantes (Hundahl, Phillips, & Menck, 2000). Apesar da dimensão 
do problema a nível mundial, diferentes taxas de prevalência entre países levam à 
adoção de diferentes estratégias: no Japão realiza-se o rastreio universal da população 
por fluoroscopia, seguida pela endoscopia digestiva alta convencional com biópsias 
para os resultados positivos (Hamashima, Shibuya et al., 2008) enquanto na maioria 
dos outros países desenvolvidos, as baixas taxas de incidência tornam o rastreio 
demasiado dispendioso (Hirota, Zuckerman et al., 2006). Em Portugal, a taxa de 
incidência de cancro gástrico está localizada entre estas duas realidades, não sendo 
fácil definir no nosso país qual a opção mais custo-eficaz. 
Este tipo de carcinoma pode ocorrer após vários anos de progressão de uma condição 
benigna como seja a gastrite não atrófica, que pode evoluir para condições pré-
malignas como a gastrite crónica atrófica ou a metaplasia intestinal, antes do 
desenvolvimento final de displasia e cancro invasivo (Correa, 1992). A endoscopia é 
geralmente o primeiro exame a efetuar para o diagnóstico destas condições pré-
malignas gástricas (Hirota, Zuckerman et al., 2006). 
Com base na assunção que a gastrite crónica atrófica se inicia no antro e pode 
progredir de forma ascendente para o corpo gástrico, de modo que as condições que 
afetam o corpo são mais extensas e representam estádios mais avançados da doença, 
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tem sido sugerido discriminar este fenótipo mais extenso que poderia implicar um 
risco aumentado de progressão para displasia e cancro invasivo. Assim sendo, 
recomendações recentes sugerem uma vigilância endoscópica a cada 3 anos destes 
pacientes, recomendações essas baseadas em dados clínicos mas sem o apoio dos 
estudos económicos disponíveis devido a resultados discordantes (Dinis-Ribeiro, Areia 
et al., 2012; Dinis-Ribeiro, Areia et al., 2012). 
Tendo Portugal uma população de risco intermediário para cancro gástrico 
(GLOBOCAN, 2012), para melhorar a taxa de sobrevivência e a qualidade de vida dos 
pacientes, é importante melhorar os índices de deteção do cancro gástrico precoce, a 
fim de permitir tratamentos curativos através de técnicas de excisão endoscópica ou a 
deteção de cancros invasivos em estádios iniciais, passíveis de tratamentos menos 
debilitantes ou dispendiosos. 
Assim sendo, o objetivo da presente tese foi determinar a relação de custo-utilidade 
da vigilância endoscópica cada 3 anos de pacientes com condições gástricas pré-
malignas em comparação com a ausência de vigilância. Para atingir esse objetivo foi 
realizado inicialmente duas revisões sistemáticas e um estudo transversal, de forma a 
obter os melhores dados clínicos disponíveis da população portuguesa e, em seguida, 
uma análise económica de custo-utilidade da nossa hipótese clínica de vigilância 
endoscópica. 
Para tal foi usado um modelo de Markov para comparar as duas estratégias, de uma 
perspetiva social. Os dados clínicos foram obtidos a partir das revisões sistemáticas 
referidas, os custos económicos de publicações institucionais nacionais e as utilidades 
da população portuguesa em termos Anos de Vida Ajustados à Qualidade (QALY) 
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foram obtidas do estudo transversal efetuado, utilizando o questionário EuroQol 
(EuroQol, 1990). Para a análise económica a população começa o modelo ao atingir a 
idade de 50 anos, durante um horizonte temporal de 25 anos e foi utilizada uma taxa 
de desconto anual de 3% quer para os custos quer para a eficácia. 
Os resultados do modelo mostram que a vigilância endoscópica a cada 3 anos 
condiciona uma relação de custo-efetividade incremental (ICER) de 18 336 €, abaixo do 
limiar de 36 575 € proposto pelas recomendações económicas e que esta estratégia de 
vigilância domina as opções de vigilância a cada 5 ou 10 anos. Mesmo quando o 
modelo foi avaliado em análise de sensibilidade, apenas algumas utilidades mostraram 
ser relevantes na análise determinística, enquanto a análise probabilística mostrou que 
em 78% das simulações o modelo permaneceu custo-eficaz. 
Assim, a conclusão da presente tese é que a vigilância endoscópica de pacientes com 
condições gástricas pré-malignas extensas, como sejam a presença de atrofia ou 
metaplasia intestinal no corpo gástrico, a cada 3 anos e num país de risco 
intermediário como Portugal, é custo-eficaz. 
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Gastric cancer is a health problem presenting very different degrees of magnitude 
worldwide. Its' geographical incidence varies considerably, being particularly marked in 
Eastern Asia, Central and Eastern Europe, and South and Central America and although 
a decrease in its incidence is being observed, its burden is still unacceptably high 
(Ferlay, Shin et al., 2010). In Portugal it ranks fifth in cancer deaths and its incidence is 
the highest in Western Europe (Ferlay, Parkin, & Steliarova-Foucher, 2010). 
When cancer is diagnosed so late, patients are offered treatments like surgery, 
chemotherapy or radiotherapy that are costly, impair quality of life, and still offer a 
poor prognosis, with an overall 5 year survival rate below 25% (Ferlay, Shin et al., 
2010; Hundahl, Phillips, & Menck, 2000; Karim-Kos, de Vries et al., 2008). Specifically in 
Portugal, gastric cancer is a neoplasm with a high incidence rate and most cases also 
present in advanced stages conducting to poor prognosis.  
To prevent late detection of the disease, health authorities should choose between 
primary prevention programs such as Helicobacter pylori (H. pylori) screening and 
eradication to prevent the biologic evolution from normal gastric mucosa to 
premalignant conditions and to invasive cancer or secondary prevention programmes 
like population screening or surveillance of patients at high risk for the development of 
the disease to allow gastric cancer detection in earlier stages with more favourable 
survival, preferably supported by economic analysis for the strategy adopted (Areia, 
Carvalho, Cadime, Rocha Goncalves, & Dinis-Ribeiro, 2013; Dinis-Ribeiro, Areia et al., 
2012; Dinis-Ribeiro, Areia et al., 2012; Malfertheiner, Megraud et al., 2012). Secondary 
prevention is usually based on endoscopy because it is widely available, accurate, 
involves relatively minor invasiveness and offers the chance of simultaneously 
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performing diagnostic biopsies and/or therapeutic procedures (Hirota, Zuckerman et 
al., 2006). 
This choice of a screening or surveillance strategy depends on the incidence of the 
disease and while in Japan endoscopic screening is considered cost-effective, in most 
countries the balance between endoscopic costs and gastric cancer treatment gains 
renders screening not cost-effective (Areia, Pimentel-Nunes, Marcos-Pinto, & Dinis-
Ribeiro, 2013; Dinis-Ribeiro, Areia et al., 2012; Dinis-Ribeiro, Areia et al., 2012; 
Hamashima, Shibuya et al., 2008). 
The intestinal subtype of gastric adenocarcinoma is known to be preceded by a 
cascade of premalignant conditions and lesions, namely chronic atrophic gastritis, 
intestinal metaplasia and gastric dysplasia (Correa, 1988; Lauren, 1965) and several 
different classifications exist for their histological classification (Capelle, de Vries et al., 
2010; Dixon, Genta, Yardley, & Correa, 1996; Rugge, Correa et al., 2002; Rugge, Meggio 
et al., 2007). One reason for this late detection in advanced stages of disease might be 
the fact that, until 2012, there were no international recommendations to guide 
clinicians in their care of individuals with these changes and this lead to a wide 
heterogeneity of practice and failure to diagnose patients with curable forms of cancer 
in most countries (de Vries, van Grieken et al., 2008; Dinis-Ribeiro, Lopes, da Costa-
Pereira, & Moreira-Dias, 2008). 
Based on the assumption that chronic gastritis starts in the antrum and then spreads 
to the corpus in an upward manner so that conditions of the corpus are more 
extensive and related to more advanced stages, it has been suggested to discriminate 
this extensive phenotype at an increased risk of progression to dysplasia and invasive 
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cancer (Dinis-Ribeiro, Areia et al., 2012). The surveillance of patients with these lesions 
might allow the endoscopic treatment of dysplastic lesions or the detection of early 
invasive cancers that are treatable with less demanding and cheaper treatments with 
better prognosis (Correa, 1992; Dinis-Ribeiro, Lopes et al., 2004; Dinis-Ribeiro, 
Pimentel-Nunes et al., 2009; NCCN, 2013). 
Recently published guidelines suggested a 3-yearly endoscopic surveillance for the 
follow-up of patients with high risk conditions of progression, such as the presence of 
extensive atrophy or intestinal metaplasia (Dinis-Ribeiro, Areia et al., 2012; Dinis-
Ribeiro, Areia et al., 2012) but only three studies have been published so far on the 
subject. 
These three studies published on the surveillance of patients with extensive conditions 
reported conflicting results on the cost-effectiveness of this option: one concluding on 
the cost-effectiveness of annual surveillance of these patients but the other two 
providing incremental cost-effectiveness ratios above the accepted threshold, 
probably related to different assumptions on rates of progression of these conditions 
(Dinis-Ribeiro, da Costa-Pereira, Lopes, & Moreira-Dias, 2007; Hassan, Zullo et al., 
2010; Yeh, Hur, Kuntz, Ezzati, & Goldie, 2010). 
One of these studies represents the only cost-effectiveness study ever conducted on 
the gastric cancer issue in Portugal, and consisted of a specific endoscopic technology 
(magnification chromoendoscopy) on a yearly basis for patients at-risk for gastric 
cancer (patients with chronic atrophic gastritis and intestinal metaplasia) (Dinis-
Ribeiro, da Costa-Pereira, Lopes, & Moreira-Dias, 2007). For the use of conventional 
upper endoscopy on a 3-yearly surveillance protocol for high-risk patients as suggested 
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from the guidelines, no such study was ever conducted raising the need for the 
present research. 
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Gastric cancer burden 
 
Gastric cancer is a worldwide problem due to its high mortality as in most cases 
patients present in advanced stages of the disease. It is the fourth most common 
malignancy and the second leading cause of cancer death just after lung cancer  
representing 9.7% of the total mortality with a estimated number of 990,000 new 
cases per year and 738,000 deaths (Ferlay, Shin et al., 2010) and although a decrease 
in its incidence is being observed (it ranked first worldwide in 1975), its burden is still 
unacceptably high (Ferlay, Shin et al., 2010; Parkin, Stjernsward, & Muir, 1984). 
In Portugal it ranks fifth in cancer deaths and its incidence is the highest in Western 
Europe with 3,018 cancers diagnosed in 2012 (Ferlay, Parkin, & Steliarova-Foucher, 
2010; GLOBOCAN, 2012). 
Most cases are related to infection with Helicobacter pylori and other environmental 
agents and so incidence increases with age. Due to the expected increase aging of 
populations, namely in Portugal, the estimates for the next 20 years will have an 
increase in incidence and mortality compared to the present time, empathising the 
burden of this disease for the next decades (GLOBOCAN, 2012) (Figure 1). 
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Figure 1 Incidence of gastric cancer in Portugal in 2012 and expected rate for the year 
2035, according to the GLOBOCAN estimates  
 
 
 
Legend: Gastric cancer cases in Portugal (GLOBOCAN, 2012). The bars in yellow represent the incidence 
cases in 2012, per gender, while the bars in blue represent the estimated increase by 2035 due to the 
increasing effect of age in the Portuguese population. 
 
Progression of gastric premalignant conditions and lesions to invasive cancer 
 
Gastric cancer is a disease that embraces several histological types but most cases are 
represented by the adenocarcinoma type that rises from the mucosal layer and among 
these, there are two types with very distinct clinical, morphological e prognostic 
characteristics (Abrams & Wang, 2010). 
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The intestinal subtype represents more than 95% of all adenocarcinoma, usually comes 
above the age of 50 years, is highly related to environmental factors namely infection 
with H. pylori and dietary risk factors, is the predominant form in countries with a high 
incidence of gastric cancer and is the final stage of a progression along many years of a 
cascade of premalignant conditions such as atrophy or intestinal metaplasia that might 
evolve to malignant non invasive lesions with dysplasia and finally to invasive cancer. 
The diffuse type represents less than 5% of cases, most of the times diagnosed before 
the age of 50, is related to genetic factors namely mutation in the gene CDH1 which 
encodes the cell adhesion molecule E-cadherin, lacks glandular structure and consists 
of poorly cohesive cells that infiltrate the wall of the stomach and has a rapid 
progression to invasiveness and spread to other organs, conditioning a usually worse 
prognosis (Carneiro, Machado, Seruca, & Sobrinho-Simoes, 1999; Carneiro, Oliveira, 
Suriano, & Seruca, 2008; Guilford, Hopkins et al., 1998; Lynch, Kaurah et al., 2008; 
Machado, Oliveira et al., 2001; Machado, Soares et al., 1999; Oliveira, Ferreira et al., 
2004). 
The most common intestinal type of adenocarcinoma has its prevalence related to 
male gender, increasing age and high prevalence regions, indicating environmental 
factors as risk factors for the disease. The accepted model for development of this type 
of cancer involves a cascade of premalignant conditions occurring over several years, 
due to environmental and host factors, which might progress to malignant non 
invasive lesions and invasive cancer (Carneiro, Machado et al., 2001; Correa, 1992; Fox 
& Wang, 2007; Ihamaki, Saukkonen, & Siurala, 1978). This model is also known as the 
Correa cascade of gastric carcinogenesis (Correa, 1992) (Figure 2): 
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Figure 2 Correa cascade of gastric carcinogenesis 
 
 
Legend: Correa pathway of pathologic events in gastric adenocarcinoma (Fox & Wang, 2007). The 
normal mucosa, over a long period of time (several years) and due to the exposure to environmental 
and increased susceptibility due to host factors, might evolve to inflammation that will allow the 
development of premalignant conditions (atrophy and intestinal metaplasia) occurring in a cascade 
which might progress to malignant non invasive lesions (dysplasia) and invasive cancer. 
 
Several observational studies have shown that environmental factors play a part and 
salt, nitrates, tobacco and H. pylori are the most fully described agents. H. pylori is the 
single main risk factor and considered to promote the development of these precursor 
conditions and lesions (Marshall & Warren, 1984). The first of these may be gastric 
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inflammation that progresses to loss of appropriate glands (atrophy), replacement of 
original glands with intestinal metaplasia glands that might develop into dysplasia and 
finally into invasive carcinoma. 
 
Helicobacter pylori infection was first considered a class I carcinogen at the 
International Agency on Research for Cancer in 1994 and is a chief risk factor for the 
intestinal type of gastric cancer (IARC, 1994). It is initially acquired in the childhood and 
it is believed to cause an inflammation that might proceed to more advanced 
conditions and ultimately to invasive cancer (Banatvala, Mayo et al., 1993; Uemura, 
Okamoto et al., 2001). Overall, H. pylori infected patients are at risk for development 
of chronic atrophic gastritis and patients who are genetically predisposed to develop 
atrophy in response to H. pylori infection are the ones who are predisposed to gastric 
cancer (Abrams & Wang, 2010; Correa, Haenszel et al., 1990; Kuipers, 1998).  
Chronic inflammation can lead to atrophy and intestinal metaplasia and both confer 
risk for the development of gastric cancer as they constitute the background in which 
dysplasia and invasive adenocarcinoma develop (Asaka, Sugiyama et al., 2001; Genta, 
1998; Kuipers, Uyterlinde et al., 1995; Rokkas, Filipe, & Sladen, 1991). Rates of 
progression to atrophy and intestinal metaplasia in patients with chronic gastritis vary 
widely among studies, ranging between 0.5% to 1.8 % and 0% to 10%, per year, 
respectively  but overall, the gastric cancer risk is too low to justify endoscopic 
surveillance in all patients with these lesions (Dinis-Ribeiro, Areia et al., 2012; Kuipers, 
Uyterlinde et al., 1995). 
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In the clinical setting, severity of atrophy and intestinal metaplasia should be graded 
and incorporated into scales developed for that purpose, such as the updated Sidney 
system (combining topographic, morphological and etiological information) (Dixon, 
Genta, Yardley, & Correa, 1996). Although intra and inter observer agreement is better 
for intestinal metaplasia than for atrophy, both have low rates of correlation and are 
difficult to translate to a clinically meaningful score. As so, another appealing 
alternative is to use the extension of atrophy or intestinal metaplasia among the 
gastric mucosa to define a subgroup of patients harbouring a higher risk for 
progression to cancer. 
When considering that their topographic extension in the gastric mucosa is relevant, 
patients presenting with atrophy or intestinal metaplasia in the corpus could represent 
a subgroup of higher risk patients for whom a specific surveillance programme is 
recommended (Kuipers & Siersema, 2004). The successors of the updated Sydney 
System such as the OLGA (Operative Link for Gastritis Assessment) (Rugge, de Boni et 
al., 2010; Rugge, Meggio et al., 2007; Satoh, Osawa et al., 2008) and the OLGIM 
systems (Operative Link on Gastric Intestinal Metaplasia) (Capelle, de Vries et al., 2010; 
Rugge, Fassan et al., 2011) accomplish this objective by incorporating not only the 
grade but also the extension of atrophy or intestinal metaplasia, respectively. They 
require that biopsies taken from the gastric mucosa during endoscopy are collected in 
separate containers from the antrum and the corpus and the histological report can 
them define grades 3 or above of atrophy or intestinal metaplasia extension that 
represents those patients with extensive conditions where endoscopic surveillance 
might be justified. Table 1 and table 2 represent the OLGA and the OLGIM grading 
systems: 
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Table 1 The OLGA system (Operative Link for Gastritis Assessment) 
  Corpus 
 Atrophy score 
No atrophy 
(Score 0) 
Mild atrophy 
(Score 1) 
Moderate atrophy 
(Score 2) 
Severe atrophy 
(Score 3) 
Antrum 
(including 
incisura 
angularis) 
No atrophy (score 0) Stage 0 Stage I Stage II Stage II 
Mild atrophy (score 1) Stage I Stage I Stage II Stage III 
Moderate atrophy (score 2) Stage II Stage II Stage III Stage IV 
Severe atrophy (score 3) Stage III Stage III Stage IV Stage IV 
 
Legend: The Operative Link for Gastritis Assessment table by combining information on atrophy in both 
the antrum and corpus (Rugge, Meggio et al., 2007). Biopsies from the antrum and corpus should be 
evaluated for the presence and severity of atrophy in separate, providing a 2x2 table and defining five 
stages of atrophy severity. Stages III and IV represent patients with an extensive condition. 
 
Table 2 The OLGIM system (Operative Link on Gastric Intestinal Metaplasia) 
  Corpus 
 Intestinal metaplasia score 
No intestinal metaplasia 
(Score 0) 
Mild intestinal 
metaplasia 
(Score 1) 
Moderate intestinal 
metaplasia 
(Score 2) 
Severe intestinal 
metaplasia 
(Score 3) 
Antrum 
(including 
incisura 
angularis) 
No intestinal metaplasia 
 (score 0) 
Stage 0 Stage I Stage II Stage II 
Mild intestinal metaplasia 
 (score 1) 
Stage I Stage I Stage II Stage III 
Moderate intestinal 
metaplasia 
 (score 2) 
Stage II Stage II Stage III Stage IV 
Severe intestinal metaplasia 
 (score 3) 
Stage III Stage III Stage IV Stage IV 
 
Legend: The Operative Link on Gastric Intestinal Metaplasia table by combining information on intestinal 
metaplasia in both the antrum and corpus (Capelle, de Vries et al., 2010). Biopsies from the antrum and 
corpus should be evaluated for the presence and severity of intestinal metaplasia in separate, providing 
a 2x2 table and defining five stages of intestinal metaplasia severity. Stages 3 or 4 represent patients 
with an extensive condition. 
48 
 
 
Other factors are related to progression of these conditions to invasive cancer but 
their role in the clinical practice is still questionable and difficult to apply in the clinical 
practice decisions such as the strain of the H. pylori, duration of infection, presence or 
absence of other environmental risk factors (e.g., poor diet, smoking, salt), host 
genetic factors, in particular genes that regulate expression of pro inflammatory 
agents (interleukin 1 β, tumour-necrosis factor) and some innate immunity receptors 
such as toll-like receptors (TLRs) (Abrams & Wang, 2010; Kuipers, Perez-Perez, 
Meuwissen, & Blaser, 1995; Machado, Figueiredo et al., 2003; Machado, Pharoah et 
al., 2001; Pereira, Sousa et al., 2006; Pimentel-Nunes, Afonso et al., 2011; Pimentel-
Nunes, Goncalves et al., 2013; Pinto-Correia, Sousa et al., 2006). Familial aggregation 
of gastric cancer also might have some role in about 10% of cases suggesting that a 
specific surveillance might be desirable, although this is still not consensual (Marcos-
Pinto, Carneiro et al., 2012; Marcos-Pinto, Dinis-Ribeiro et al., 2012). 
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Endoscopy 
 
Upper digestive endoscopy is considered the ideal procedure for the diagnosis of 
upper digestive system diseases involving the oesophagus, stomach and duodenum. Its 
widespread availability, the improved accuracy for most diseases, its relatively minor 
invasiveness and the possibility of simultaneously performing diagnostic biopsies 
and/or therapeutic procedures usually makes it the first choice for the study of upper 
digestive diseases (Hirota, Zuckerman et al., 2006). It is usually the first exam 
performed for the diagnosis of gastric premalignant conditions in patients with gastric 
complaints but its cost precludes its use as screening tool for gastric cancer in most 
clinical scenarios. 
Even though some efforts at developing screening or diagnostic methodologies to 
determine the presence and extent of atrophy or intestinal metaplasia have been 
made, endoscopy alone is said to be inaccurate to determine these changes and the 
gold standard for diagnosis is histology from biopsies taken during upper endoscopy 
(Areia, Amaro et al., 2008; Areia, Amaro et al., 2008; Dinis-Ribeiro, da Costa-Pereira et 
al., 2003). 
As Portugal is the Western European country with the highest incidence of gastric 
cancer it is crucial to have data on prevalence of gastric premalignant conditions 
(Ferlay, Shin et al., 2010; Hundahl, Phillips, & Menck, 2000). Furthermore, patient 
acceptance to undergo an endoscopy and the manner in which these exams are 
performed in terms of associated techniques, use of sedation and complications are 
mandatory to quantify costs that might be relevant in further economic studies that 
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consider endoscopy for population screening or follow-up of asymptomatic at-risk 
patients in Portugal. 
 
 
Economic studies 
 
Economic studies in medicine are usually designed to compare technologies or clinical 
strategies by simultaneously addressing their differences in terms of both clinical 
benefits and the cost involved in achieving those gains (Drummond, Sculper, Torrance, 
O'Brien, & Stoddart, 2005). The objective is to compare different technologies to 
achieve the same purpose based on the assumption that financial resources are 
limited and options have to be made incorporating not only clinical effectiveness but 
also costs. This concern is mainly driven by politicians and health administrators but 
should also be adopted by health professionals and the society as well (Drummond, 
Sculper, Torrance, O'Brien, & Stoddart, 2005).  
As so, any economic study in the field of medicine is “the comparative analysis of 
alternative courses of action in terms of both their costs and consequences” and wants 
to answer simultaneously two questions: which is the best medical option for a specific 
clinical outcome and what cost is the society willing to pay to obtain that outcome 
(Drummond, Sculper, Torrance, O'Brien, & Stoddart, 2005). 
They can consider the comparators similar in terms of clinical benefits and just address 
the cost problem (cost-analysis or cost-minimization analysis) or consider the 
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comparators with different clinical benefits and then compare the different costs 
involved (cost-effective analysis). When the clinical benefits, for instance life-years 
saved (LYS), are adjusted to utilities in terms of quality of life (QALY-quality adjusted 
life years) the studies are called cost-utility analyses and, when the clinical benefit is 
transformed into a monetary value the studies are called cost-benefit analyses. 
The representation of the simultaneous costs and effects of a clinical option can be 
plotted in a cost-effectiveness plane that will have four quadrants and the willingness 
to pay frontier defined by the society is represented by a line that crosses the centre of 
the axis and runs through quadrants I and III as shown in the figure 3: 
 
Figure 3 Cost-effectiveness plane 
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Legend: The cost-effectiveness plane is a simultaneous representation of the difference between two 
strategies in terms of both costs and effects (Drummond, Sculper, Torrance, O'Brien, & Stoddart, 2005). 
Costs and effects cross in zero and while the difference in costs changes from negative to positive from 
bottom to top, the difference in effects changes from negative to positive from left to right, providing 
four quadrants named by the corresponding Roman numbers I to IV. The willingness to pay frontier 
defined by the society is represented by a line that crosses the centre of the axis and runs through 
quadrants I and III. Cost-effective strategies are placed in quadrants I and III below the willingness to pay 
frontier or in quadrant II. Δ- Difference between strategies in terms of costs or effects. √- Cost-effective 
strategies. 
 
In general, the alternative or option in study when compared with the present clinical 
practice will imply a higher cost and the difference has to be quantified and compared 
to the threshold defined by the society. When plotting effects and cost in the cost-
effectiveness plane the option in study usually comes on the right upper side 
(quadrant I) by providing more effects but at a higher expense (Black, 1990).  
Cost-effective strategies should be below the willingness to pay threshold, usually in 
the quadrant I as already mentioned. In very rare situations the new option will 
provide more effects with a lower cost (quadrant II). Other rare situations might be 
below the willingness to pay frontier in quadrant III but are discussible to the society as 
they will provide less effects although at a lower cost than the actual practice. 
The primary outcome measure for any economic evaluation is obtained by calculating 
the ratio between the difference in costs among strategies that are placed in the 
numerator and the respective difference in effectiveness that will be placed in the 
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denominator and this is called the incremental cost effectiveness ratio (ICER), as 
shown in figure 4 (Drummond, Sculper, Torrance, O'Brien, & Stoddart, 2005): 
 
Figure 4 Incremental Cost Effectiveness Ratio (ICER)  
 
 
Legend: The Incremental Cost Effectiveness Ratio is the calculation of a ratio among differences in costs 
between two strategies versus the difference in effects of the same strategies (Drummond, Sculper, 
Torrance, O'Brien, & Stoddart, 2005). Costs need to be in the same monetary currency and effects in the 
same clinical unit, like Life Years Saved (LYS) or Quality Adjusted Life Years (QALY). The first option in 
each part of the equation is the strategy in study (the study hypothesis) and the second option is the 
usual strategy in clinical practice (the current standard). ICER- Incremental Cost Effectiveness Ratio. 
 
For diseases that develop for several years and that might impair not only survival  but 
also the quality of that life as well, the standard effectiveness used are the years of life 
adjusted for they quality, namely the quality adjusted life years (QALY) (Weinstein & 
Stason, 1977), providing a cost-utility study instead of only a cost-effectiveness 
analysis. In this form of economic evaluation, the focus is on the quality of the health 
outcome produced and by incorporating the notion of value have a more broad 
applicability and are more useful to decision makers (Drummond, Sculper, Torrance, 
O'Brien, & Stoddart, 2005). Guidelines for the reporting of these studies have for many 
years recommended conducting cost-utility analysis, where the use of clinical benefits 
ICER = Cost new alternative – Cost current practice alternative 
           Effect new alternative – Effect current practice alternative 
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should be adjusted to patient preferences (Russell, Gold, Siegel, Daniels, & Weinstein, 
1996; Siegel, Weinstein, Russell, & Gold, 1996; Weinstein, Siegel, Gold, Kamlet, & 
Russell, 1996). 
Thus, utilities in terms of QALYs means that 1 year of live is multiplied by a utility factor 
between 1 and 0, providing different values for each single year of life depending on 
the quality of life of that year, resulting in a value that will vary between 1 QALY (one 
year with perfect quality of life) and 0 (death, by definition). These guidelines also 
suggest that preferences should be used by adopting population preferences instead 
of patient-reported values. 
Cost-utility analysis has the advantages in relation to cost-effectiveness analysis of 
using generic measures like QALY that potentiate comparability among studies, is a 
method to which various disparate outcomes can be combined into a single measure 
(QALY) and highlights consumer preferences or utilities, being the preferred method 
according to guidelines (Drummond & Jefferson, 1996). It is also the ideal method to 
compare cancer treatments as many of these treatments improve longevity and long-
term quality of life but decrease quality of life during the treatment process itself 
(Drummond, Sculper, Torrance, O'Brien, & Stoddart, 2005). 
Preferences are an umbrella that describes the overall concept while utilities and 
values are different types of preferences, according to the following table as described 
by Drummond and colleagues (Drummond, Sculper, Torrance, O'Brien, & Stoddart, 
2005) (Table 3): 
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Table 3 Preferences definitions and type of methods 
 Question framing 
Response method Certainty (values) Uncertainty (utilities) 
Scaling 
1 2 
Rating scale  
Category scaling  
Visual analogue scale  
Ratio scale  
Choice 
3 4 
Time trade-off Standard gamble 
Paired comparison  
Equivalence  
Person trade-off  
 
Legend: Definition of type of preferences according to the options for responding (choice or scaling) and 
the framing of questions (with certainty or uncertainty), as suggested by Drummond and colleagues 
(Drummond, Sculper, Torrance, O'Brien, & Stoddart, 2005). 
 
In summary, options in sectors 1 and 3 measure values will those in sector 4 measure 
utilities. For the calculation of preferences, when using a cardinal measurement, the 
number must be attached to an outcome that in some sense represents the 
preference for that outcome in comparison to other and in theory in should be in an 
interval scale and equal intervals should mean the same difference along the scale 
(Drummond, Sculper, Torrance, O'Brien, & Stoddart, 2005). 
There is no best method and measuring preferences with most of these options are 
time consuming and complex. As so, in many cases, authors use pre-scored multi-
attribute health status classification systems such as the EQ-5D-5L from the EuroQol 
group as we did for the present thesis (EuroQol, 1990). The preferences scoring for this 
specific system was done using the time trade-off technique in around 3,000 United 
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Kingdom adults with the final scores falling in between 0 (death) and 1 (perfect health) 
(Dolan & Gudex, 1995; EuroQol, 1990; Herdman, Gudex et al., 2011). 
Our option on this EQ-5D-5L health status classification system is the result of several 
advantages: the instrument is established for a long time, is feasible, reliable and valid 
according to hundreds of published studies, it accommodates attributes that might be 
relevant for patients with gastric cancer or submitted to treatments for it but at the 
same time is very general allowing for application and comparison to “healthy” 
subjects, it is the recommended instrument by the National Institute for Clinical 
Excellence, it is not very time consuming, is easily applicable even by less instructed 
patients and finally is available in Portuguese language and was already used in 
Portuguese gastric cancer patients in the past allowing for comparison of results 
(Drummond, Sculper, Torrance, O'Brien, & Stoddart, 2005; EuroQol, 1990; Ravasco, 
Monteiro-Grillo, & Camilo, 2003). 
Although the EQ-5D-5L questionnaire still has no population norms published for the 
Portuguese population, the older but similar EQ-5D-3L system had only recently set 
the preferences for the general population using the time trade-off technique and also 
developed population norms, unfortunately both only after the development of the 
present thesis and associated studies (Ferreira, Ferreira, Pereira, & Oppe, 2014, 2014). 
Because currently there is no validated method to transform utilities from the EQ-5D-
3L to the EQ-5D-5L systems, we used the Spanish EQ-5D-5L utilities. From the available 
options Spanish utilities are the most similar, providing a Pearson’s correlation 
coefficient of r=0.946 for both EQ-5D-3L population norms (Ferreira, Ferreira, Pereira, 
& Oppe, 2014). 
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Data from several authors suggests that independently of the pre-scored multi-
attribute health status classification system used, health preferences measurements 
does not vary significantly as a function of demographic variables, including race, 
income, gender, population or country (Kaplan, 1994; Kaplan & Anderson, 1988; Wang, 
Furlong, Feeny, Torrance, & Barr, 2002). Also, some authors argue that utility-weighted 
QALY is a good approximation of utilities in most situations and a good basic definition 
of what is trying to be achieve in health care (Culyer & Wagstaff, 1993; Garber & 
Phelps, 1997). 
The willingness to pay frontier most widely used is 50,000 United States Dollars (USD) 
per LYS or per QALY and this value will allow for comparability among results of 
different models (Shillcutt, Walker, Goodman, & Mills, 2009).  Other possibility for this 
controversial point could be the adoption of a threshold of twice the gross national 
income per capita as suggested by some institutions (Garber & Phelps, 1997; Sachs, 
2001; Tan-Torres Edejer, Baltussen et al., 2003). Independently of the choice, the 
willingness to pay threshold should be further converted to the local currency of the 
modelled population (WorldBank, 2013). For Portugal, the option for the USD 50,000 
would be 36,575 Euros (€) at a 2013 exchange rate and the option based on the gross 
national income per capita would be quite similar, USD 41,240 or € 30,433 after 
conversion. 
Finally, the analysis of the model has to be contextualized in terms of the perspective 
used, meaning that the costs that are incorporated might vary depending on the 
viewpoint adopted. Guidelines propose that the society perspective is the best option 
as it will incorporate all available costs independently of the professional group 
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affected, including costs related to the patient, relatives, employers, national health 
system or insurance companies but other options are used as well such as the health 
system, the payer or the patient’ perspectives only. Depending on the perspective, 
different cost will be incorporated such as the direct medical costs of the alternatives 
but also the costs of further surveillance appointments or exams, costs in 
transportation, outpatient support, productivity changes or costs for absenteeism 
(Caro, Briggs, Siebert, Kuntz, & Force, 2012; Drummond & Jefferson, 1996). 
 
Published economic studies on endoscopic surveillance of patients 
 
Several studies were published so far on the subject of cost-effectiveness for gastric 
cancer but many of them were conducted from a primary prevention perspective 
through H. pylori eradication (Davies, Crabbe et al., 2002; Leivo, Salomaa et al., 2004; 
Mason, Axon et al., 2002; Parsonnet, Harris, Hack, & Owens, 1996; Roderick, Davies et 
al., 2003; Roderick, Davies et al., 2003; Yeh, Kuntz, Ezzati, & Goldie, 2009) and only a 
few concerned the use of endoscopic techniques to increase detection of early lesions 
(Dan, So, & Yeoh, 2006; H. Y. Lee, Park, Jun, Choi, & Hahm, 2010; Y. C. Lee, Lin et al., 
2007) or to follow-up of premalignant conditions (Dinis-Ribeiro, da Costa-Pereira, 
Lopes, & Moreira-Dias, 2007; Hassan, Zullo et al., 2010; Yeh, Hur, Kuntz, Ezzati, & 
Goldie, 2010) (Table 4). 
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Table 4 Studies on follow-up of individuals with premalignant conditions and lesions 
Study 
(1st author, year) 
Intervention 
(Population) 
Result - ICER Threshold 
Unit 
Conclusion 
Dinis-Ribeiro, 2007 Yearly magnification 
chromoendoscopy + 
Serum Pepsinogens 
(Portugal) 
1,868 per QALY 50,000 
 Euros 
Follow-up of patients 
with atrophic chronic 
gastritis and intestinal 
metaplasia is cost-
effective 
Hassan, 2010 Yearly endoscopy 
(United States) 
72,519 per LYS 100,000 
USD 
Yearly endoscopy is 
cost-effective in 
patients with intestinal 
metaplasia 
Yeh, 2010 Endoscopic 
surveillance every 1, 
5 or 10 years 
(United States) 
39,800 per QALY for 
dysplasia 
544,500 per QALY for 
intestinal metaplasia 
50,000 
USD 
Endoscopic 
surveillance of 
intestinal metaplasia is 
not cost-effective 
Legend: ICER- Incremental Cost Effectiveness Ratio, QALY- Quality Adjusted Life Years, LYS- Life Years 
Saved, USD- United States Dollars. 
 
Main research question 
In light of this, our thesis main research question was to determine the cost-utility of 
endoscopic surveillance of patients with extensive gastric premalignant conditions in 
Portugal. 
In order to answer this question we performed an economic analysis on the secondary 
prevention of gastric adenocarcinoma by endoscopic surveillance of patients at high 
risk of progressing because of extensive atrophy lesions or intestinal metaplasia. The 
study was designed for the Portuguese population because Portugal has the highest 
incidence of the disease in Western Europe, the model chosen was a cost-utility 
Markov model using a societal perspective and the main option was set for a 3-yearly 
surveillance schedule according to guidelines suggestion. 
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Chapter III - Aims 
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The aim of our first study was to conduct a systematic review of studies on cost-
effectiveness of upper digestive endoscopy, to obtain the state-of-the-art on economic 
studies for gastric cancer screening and surveillance of premalignant conditions or 
lesions. A systematic review of the published literature was undertaken, irrespective of 
the technology used, type of cost study or clinical scenario, to address in the published 
literature what was the reported cost-effectiveness of strategies for gastric cancer 
screening and surveillance of premalignant conditions or lesions versus taking no 
action. 
 
The aim of our second study was to conduct a systematic review and meta-analysis of 
studies reporting premalignant conditions (atrophy or intestinal metaplasia) detected 
by upper digestive endoscopy in both screening and surveillance settings, from a 
sensitive search in several databases, to assess the global prevalence of gastric 
premalignant conditions in an aggregated manner by performing a meta-analysis of 
results and their relation with the gastric cancer incidence of the studied population; 
secondary objectives were to study the differences in prevalence concerning the 
methods of assessment, gender, age and H. pylori infection. 
 
The aim of our third study was to conduct a cross-sectional study to obtain health 
utilities from the Portuguese population that would include patients without gastric 
lesions and also with all sorts of upper gastrointestinal diseases, including patients 
with all ranges of gastric premalignant conditions and patients with gastric cancer 
submitted to all available treatments namely endoscopic, surgery, chemotherapy, 
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radiotherapy or just best supportive care. The pre-scored multi-attribute health status 
classification system used was the Portuguese version of the EQ-5D-5L questionnaire 
and the reference test for the diagnosis was the gastroenterologist diagnosis, including 
the histopathology result when applicable. 
 
Finally, the aim of our forth study and also the final aim of this thesis were to 
determine the cost-utility of performing a 3 yearly endoscopic surveillance of high risk 
patients with extensive premalignant conditions versus no surveillance for the 
Portuguese population, an intermediate incidence population for gastric cancer. 
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Improving survival of gastric cancer patients might be achieved by increasing the 
detection of lesions in an earlier stage and that goal could be accomplished by the 
surveillance of high-risk patients with extensive premalignant conditions at risk of 
progressing to invasive cancer. An endoscopic surveillance schedule every 3-years was 
suggested in recent guidelines on a clinical basis but better studies are needed to show 
its cost-effectiveness (Areia, Carvalho, Cadime, Rocha Goncalves, & Dinis-Ribeiro, 
2013; Dinis-Ribeiro, Areia et al., 2012; Dinis-Ribeiro, Areia et al., 2012). 
The objective of the present thesis was to determine the cost-utility of this endoscopic 
surveillance every 3 years in patients with extensive gastric premalignant conditions 
compared with no surveillance. To accomplish that goal we first performed two 
systematic reviews and one cross-sectional study in order to obtain the best available 
clinical data for the Portuguese population and then a cost-utility economic analysis on 
this hypothesis. 
 
Preliminary studies 
 
With our first systematic review of studies on the subject of cost-effectiveness of 
gastric cancer screening or surveillance, we think to have accomplished the objective 
of obtaining the best available evidence published so far (Areia, Carvalho, Cadime, 
Rocha Goncalves, & Dinis-Ribeiro, 2013). That information was very helpful for the 
conception of our model and also by providing both strengths and weaknesses of the 
available evidence. 
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We concluded that endoscopy was more cost-effective than no screening but 
depended mainly on its cost (Dan, So, & Yeoh, 2006; Gupta, Bansal et al., 2011; 
Tashiro, Sano, Kinameri, Fujita, & Takeuchi, 2006; Zhou, Guan et al., 2011). When 
different schedule options for endoscopic screening were analyzed, the ICER results 
would vary but still remain below the USD 50,000 threshold. These results were in 
accordance with a recent endoscopic screening study from a high-risk population in 
Korea that concluded that endoscopic intervals of 3 years or below showed similar 
protective benefits in relation to the detection of an advanced gastric cancer stage 
disease (Nam, Choi et al., 2012). This result supports our option on modelling the cost-
effectiveness of endoscopy instead of other technologies. 
We also concluded that in respect of endoscopic follow-up of patients with 
premalignant conditions the available evidence was contradictory and limited to 3 
studies, with one European model claiming that the surveillance of patients with 
extensive atrophy or intestinal metaplasia was cost-effective (Dinis-Ribeiro, da Costa-
Pereira, Lopes, & Moreira-Dias, 2007) whilst a model for the American population with 
intestinal metaplasia concluded that surveillance presented a ICER that was above the 
usually accepted threshold in most economic analyses (Hassan, Zullo et al., 2010). A 
third model, also for the American population, concluded that endoscopy was cost-
effective only in patients with dysplasia but not for intestinal metaplasia (Yeh, Hur, 
Kuntz, Ezzati, & Goldie, 2010). These conflicting results seemed to be related to 
different assumptions on the progression or regression of conditions, assessment of 
extension of premalignant conditions, estimates for the 5-year stage specific mortality 
but also on costs of endoscopy and dissimilar populations. These results showed that 
this field of endoscopic surveillance of premalignant conditions clearly needed more 
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economic studies, models and better scientific evidence, further supporting the aim of 
the present thesis. 
Finally, we also concluded that the published studies presented several problems 
according to the guidelines suggestions (Drummond & Jefferson, 1996), that we have 
identified and would not want to repeat in our model, such as: models not using the 
“no action” option in the reference case (Tashiro, Sano, Kinameri, Fujita, & Takeuchi, 
2006), only three articles adopting the societal perspective recommended (Y. C. Lee, 
Lin et al., 2007; Yeh, Hur, Kuntz, Ezzati, & Goldie, 2010; Yeh, Kuntz, Ezzati, & Goldie, 
2009), only one third of the studies using both length of time (LYS) and quality of that 
time (QALY) as effectiveness estimates, and most studies using patient preferences 
instead of the recommended community preferences (Dan, So, & Yeoh, 2006; Dinis-
Ribeiro, da Costa-Pereira, Lopes, & Moreira-Dias, 2007; Gupta, Bansal et al., 2011; Xie, 
Luo, Blackhouse, Goeree, & Lee, 2008; Xie, Luo, & Lee, 2008; Xie, O'Reilly et al., 2009; 
Yeh, Hur, Kuntz, Ezzati, & Goldie, 2010; Yeh, Kuntz, Ezzati, & Goldie, 2009; Zhou, Guan 
et al., 2011). 
With our second systematic review we think to have provided the first systematic 
review and meta-analysis on the global prevalence of gastric premalignant conditions 
published so far and their relation with the gastric cancer incidence of the studied 
population (Marques-Silva, Areia, Elvas, & Dinis-Ribeiro, 2014). The result on the 
prevalence of extensive conditions would be very helpful by providing further evidence 
on this prevalence rate and allowing some validation of our final model estimates 
versus real life values. 
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We concluded that the prevalence of extensive gastric premalignant conditions was 
only 7% in countries with low to moderate incidence of gastric cancer but in countries 
with high incidence such as Portugal it reached 16% for extensive intestinal metaplasia 
and 27% for extensive atrophy. These estimates reinforced the relevance of this 
prevalence rate of patients harbouring a high-risk phenotype to which endoscopic 
surveillance could be offered, as we wanted to model in our thesis. 
With our cross-sectional study we obtained health utilities from a Portuguese 
population that included patients without gastric lesions, with all sorts of upper 
gastrointestinal diseases, all ranges of premalignant gastric conditions and also with 
gastric cancer, submitted to all available treatments, including endoscopic, surgery, 
chemotherapy, radiotherapy or just best supportive care (Areia, Alves et al., 2014). 
This information was essential to the development of our final model by allowing the 
construction of a cost-utility model instead of a cost-effective one. Also, the utility data 
obtained, specific for the Portuguese, would be just perfect for a model idealized for 
the Portuguese population and would provide utility values for all disease stages 
necessary for building the model. 
We concluded that health utilities measured by the EQ-5D-5L questionnaire was 
feasible and showed similar scores for patients without gastric lesions (0.78), patients 
with premalignant conditions (0.82) and patients with previously treated gastric cancer 
(0.77-0.79) but lower values for patients with present carcinoma (0.66) and that, for 
the same clinical situations, EQ-5D-5L scores were always lower for female than for 
male. This conclusion was very important for the final economic results of our model 
by pointing out the fact that utilities may not vary so much between different clinical 
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situations along the gastric carcinogenesis cascade as suggested by other published 
studies, and that wider published values in the available literature might have resulted 
from the use of different questionnaires in different clinical situations. Also, male and 
female provided different perceptions of utility for the same situations and that result 
should be incorporated in our final model. 
We also compared our results to the published studies used in previous cost-utility 
analysis and concluded that several problems existed within the methodology of the 
published literature that we think to have overcome with the present study. Examples 
of such problems detected: no values for the asymptomatic population (Dan, So, & 
Yeoh, 2006; Dinis-Ribeiro, da Costa-Pereira, Lopes, & Moreira-Dias, 2007; Gupta, 
Bansal et al., 2011; Xie, Luo, Blackhouse, Goeree, & Lee, 2008; Xie, Luo, & Lee, 2008; 
Xie, O'Reilly et al., 2009; Zhou, Guan et al., 2011); use of 1 as the value for the normal 
population (Xie, Luo, Blackhouse, Goeree, & Lee, 2008; Zhou, Guan et al., 2011); only 
one study had values for gastric premalignant conditions (Yeh, Hur, Kuntz, Ezzati, & 
Goldie, 2010); only one study had values for the post mucosectomy stage (Dinis-
Ribeiro, da Costa-Pereira, Lopes, & Moreira-Dias, 2007); only two models presented 
more than a single value for all gastric cancer patients, irrespective of type of 
treatment performed (Dan, So, & Yeoh, 2006; Dinis-Ribeiro, da Costa-Pereira, Lopes, & 
Moreira-Dias, 2007) and finally only two authors used a single reference to obtain the 
utilities for their models: the study by Wang Q et al (Wang, Jin, Lin, Xu, & Chen, 2003) 
that is in Chinese and not available to most clinicians, and the study by Dinis-Ribeiro et 
al (Dinis-Ribeiro, da Costa-Pereira, Lopes, & Moreira-Dias, 2007) that used a systematic 
review of studies embracing several different questionnaires on patients with 
diagnosed or treated gastric cancer. 
126 
 
Cost-utility model 
 
When modelling the strategy of endoscopic surveillance of patients with extensive 
premalignant lesions by endoscopy every 3 years, we concluded that it was cost-
effective (Areia, Dinis-Ribeiro, & Rocha Goncalves, 2014). 
We concluded that our model showed an incremental cost effectiveness ratio (ICER) of 
only € 18,336 per QALY, well below the usual willingness-to-pay threshold of USD 
50,000, equal to € 36,575 at a 2013 exchange rate and also below the € 30,433 
threshold if the option was based on the gross national income (Shillcutt, Walker, 
Goodman, & Mills, 2009). 
Surveillance at every 5 or 10 years were dominated as they provided less effectiveness 
(probably due to the increased cases of advanced gastric cancer) at similar costs (less 
costs on surveillance but more costs for advanced disease treatments). This confirmed 
our clinical perception that was published in the guidelines (Dinis-Ribeiro, Areia et al., 
2012) that a 3-year interval seemed to be in good balance between a very intensive 
surveillance (possible increase detection at an increased cost) and a more spaced 
surveillance that might be losing early lesions (and decreasing effectiveness). 
We also concluded that the results were robust in sensitivity analyses, as variables 
evaluated by one-way deterministic analysis remained below the threshold in all cases 
even in the extremes of the range used, except for utilities of patients submitted to 
endoscopic submucosal dissection but only at an unrealistic lowest range, even below 
the utility of patients with present cancer. 
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Furthermore, the Monte Carlo probabilistic analysis revealed that even when 
simulating all variables together, in 78% of simulations the ICER would fall below the 
willingness-to-pay threshold. These results further support our conclusion that an 
endoscopic surveillance every 3 years in this specific population was cost-effective. 
Modelling has evolved considerably since the first study on surveillance of patients 
with extensive conditions was published in 2007 by Dinis-Ribeiro et al (Dinis-Ribeiro, da 
Costa-Pereira, Lopes, & Moreira-Dias, 2007) but we think our model has some 
strengths that serve to enrich our conclusions and help explain the discrepancies in the 
conclusions published so far. 
Not all the studies adopted a cost-utility calculation that incorporated QALY and a 
societal perspective by including the cost to patients and to employers, as ours does. In 
fact, our study is the only one to use utilities specific to the population included, rather 
than adopting preferences from the literature but from different populations (Areia, 
Alves et al., 2014). The references used for the variables are supported in a previously 
published systematic review (Areia, Carvalho, Cadime, Rocha Goncalves, & Dinis-
Ribeiro, 2013) and most references are from systematic not single studies as the other 
models did, which might not be the best available estimate. 
Our model was also much more detailed than the previous studies, all but three 
references used for clinical data were from the 5 years immediately before the year 
considered in the model, and we have included in sensitivity analysis the full range of 
progression rates from the 3 earlier models which proved to be relevant to the 
sensitivity analysis. 
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We think that by doing so we have accomplished a level 1b economic study according 
to the Oxford Levels of Evidence, by providing an “analysis based on clinically sensible 
costs or alternatives with a systematic review of the evidence and including multi-way 
sensitivity analyses” (Oxford, 2011). 
A comparison of our model with the available literature, which comprises only 3 
published models whose results disagree, is presented in Table 5 (Dinis-Ribeiro, da 
Costa-Pereira, Lopes, & Moreira-Dias, 2007; Hassan, Zullo et al., 2010; Yeh, Hur, Kuntz, 
Ezzati, & Goldie, 2010). 
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Table 5 Published models of economic studies on endoscopic surveillance of 
premalignant conditions versus no surveillance, compared to the present thesis 
Study 
(1
st
 author, 
publication year) 
Present thesis 
2013 
Dinis-Ribeiro 
2007 
Hassan 
2010 
Yeh 
2010 
Type of study Cost-utility Cost-utility Cost-effectiveness Cost-utility 
Country / Model 
Year 
Portugal 
2013 
Portugal 
2005 
USA 
2008 
USA 
2007 
Intervention Endoscopy 
every 3 years 
Chromoendoscopy 
every 1 year 
Endoscopy 
every 1 year 
Endoscopy 
every 10 years 
Perspective Societal Health service Health service Societal 
Threshold / Unit USD 50,000 
(36,575 Euros) 
Euros 50,000  USD 100,000 USD 50,000 
Population Extensive 
premalignant 
lesions 
Extensive 
premalignant 
lesions 
Intestinal 
metaplasia 
Intestinal 
metaplasia 
Sensitivity analysis One-way, 
Probabilistic 
One-way Two-way, 
Probabilistic 
One-way, 
Probabilistic 
Source of 
Effectiveness 
LYS, QALY QALY LYS QALY 
Result (ICER) € 18,336  
per QALY 
€ 1,868  
per QALY 
USD 72,519  
per LYS 
USD 544,500  
per QALY 
Relevant variables 
in sensitivity 
analysis 
Utilities Quality of life after 
surgery 
Cancer incidence 
reduction 
Surgical risks 
 Gender proportion Chemotherapy 
cost 
Cancer down-
staging 
Success of 
endoscopic 
resection 
Strengths / 
Limitations 
Strengths: Limitations: Limitations: Limitations: 
Type of review Systematic review Not detailed Not detailed Not detailed 
Model complexity Extensive Simple Simple Simple 
Number of 
variables (clinical, 
cost) 
Extensive (58, 38) Small (3, 6) Small (7, 2) Moderate (25, 10) 
Utilities Utilities from 
specific population 
Utilities from other 
populations 
No utilities Utility valuations 
not detailed 
Threshold According to 
guidelines 
Not detailed Not conventional  
Conclusion Endoscopy every 3 
years is cost-
effective for 
extensive atrophy 
or intestinal 
metaplasia 
Chromoendoscopy 
every 1 year is 
cost-effective for 
extensive atrophy 
or intestinal 
metaplasia 
Endoscopy every 1 
year is cost-
effective for 
intestinal 
metaplasia 
Endoscopy every 
10 years is not 
cost-effective for 
intestinal 
metaplasia 
Legend: USA- United States of America, LYS- Life years saved, QALY- Quality adjusted Life years, ICER- 
Incremental cost effectiveness ratio, USD- United States Dollars. 
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There are, however, some limitations in the present model. Although it is extensive, it 
does not definitely accommodate all possible clinical real life options, and it is 
impossible to know how far or how near we are to the perfect model. Also, even by 
using utilities obtained directly from the studied population,  the utilities valuation is 
also open to bias and the confidence intervals available are wide (Areia, Alves et al., 
2014). Finally, the ranges and distributions for sensitivity analysis are not generally 
available in the literature and the approximations we used might not be the best 
option. 
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Conclusion 
 
In conclusion, according to our model, endoscopic surveillance of patients with 
premalignant conditions such as extensive atrophy or intestinal metaplasia, every 3 
years, in an intermediate-risk country such as Portugal, is cost-effective. 
This strategy provides an incremental cost effectiveness ratio of only € 18,336 per 
QALY, well below the usual willingness-to-pay threshold of € 36,575 (equivalent to USD 
50,000) and also below € 30,433 if the threshold was based on the gross national 
income, while surveillance at every 5 or 10 years were dominated as they provided less 
effectiveness at similar costs. 
Our model fitted real life estimates and proved to be robust in sensitivity analyses, as 
almost all variables evaluated in one-way deterministic analysis remained below the 
threshold and in Monte Carlo probabilistic analysis 78% of simulations would fall below 
the willingness-to-pay threshold. 
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Further research 
Further studies evaluating the impact of this option are needed to confirm if 
surveillance will in fact improve early gastric cancer detection rates, increase curative 
endoscopic resections, detect invasive cancer in earlier stages and ultimately lead to 
better overall survival for gastric cancer patients. 
The hypothesis modelled in the present thesis should be replicated in other countries 
in order to confirm or not its cost-utility in other populations, particularly in countries 
with only low to moderate gastric cancer incidence. 
Moreover, effectiveness could be further studied in terms of monetary benefits by 
transforming health benefits in monetary units and performing a cost-benefit analysis, 
along the cost-utility analysis. 
Finally, screening instead of surveillance could be modelled in a similar manner, to 
decide if in a specific population it would be cost-effective to screen instead of 
surveillance and in which specific high-risk population could this strategy be offered. 
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